Welcome to our dedicated page for ARGENT BIOPHARMA news (Ticker: MGCLF), a resource for investors and traders seeking the latest updates and insights on ARGENT BIOPHARMA stock.
Argent BioPharma (MGCLF) delivers innovative biopharmaceutical solutions through advanced polypharmacology and nanotechnology approaches. This news hub provides investors and medical professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Track the company's progress in neurology and immunology research, including updates on CannEpil® for epilepsy management and CimetrA® for respiratory applications. Our curated news feed covers earnings reports, manufacturing expansions, partnership announcements, and progress toward global treatment accessibility goals.
Stay informed about Argent BioPharma's EU GMP-compliant production facilities, research collaborations, and participation in international medical conferences. Bookmark this page for real-time updates on drug development breakthroughs and financial performance from both LSE and ASX listings.
MGC Pharmaceuticals Ltd. has announced that its investigational medicinal product, CannEpil®, is now available to patients in the UK through Named Patient Request. This decision follows the success of Epidiolex, which generated
MGC Pharmaceuticals Ltd. (LSE: MXC, OTC: MGCLF) announced that its product ArtemiC™ is now listed as an OTC drug in the US, according to the FDA National Drug Code (NDC) Database. This milestone, facilitated by US partner AMCPharma USA, allows ArtemiC™ to enter US Pharmacy Benefit Management (PBM) networks by April 2023. AMC has placed a US$2 million order, with deliveries scheduled for Q3 and Q4 2023. ArtemiC™, which has shown effectiveness in treating moderate COVID-19 and chronic inflammatory diseases, was developed with Grat Bio® SNEDD technology, ensuring high bioavailability and safety.
MGC Pharmaceuticals Ltd. (OTC: MGCLF) has signed an exclusive distribution agreement with Sciensus Rare to distribute its products, CannEpil® and CogniCann®, in key European markets and the UK. This partnership aims to enhance access to CannEpil®, for drug-resistant epilepsy, and CogniCann®, for dementia and Alzheimer's patients. The agreement covers several countries including Denmark, France, Italy, Spain, Luxembourg, and the UK for an initial four years. MGC Pharma remains responsible for market authorization, while Sciensus Rare handles early access program applications.
